Gilead Sciences, Inc.
About Gilead Sciences, Inc.
Gilead Sciences is a biopharmaceutical company that discovers, develops, and commercializes innovative therapeutics in areas of unmet medical need. The company's mission is to advance the care of patients suffering from life-threatening diseases worldwide. Headquartered in Foster City, California, Gilead has operations in North America, Europe and Australia.
2130 articles about Gilead Sciences, Inc.
-
Gilead Sciences (Foster City, CA) To Release Fourth Quarter And Year End 2005 Financial Results On Monday, January 30, 2006
1/23/2006
-
Gilead Sciences (Foster City, CA) Announces The Advancement Of HIV Integrase Inhibitor GS 9137 To A Phase II Clinical Trial
1/9/2006
-
Bristol-Myers Squibb Company And Gilead Sciences (Foster City, CA) Advance Combo AIDS Treatment
1/9/2006
-
Gilead Sciences (Foster City, CA) To Repatriate About $280 MillionTo The United States
12/27/2005
-
Roche Release: FDA Extends Prophylaxis Indication For Tamiflu(R) To Children Between One To 12 Years Of Age
12/22/2005
-
John W. Madigan Joins Gilead Sciences (Foster City, CA) Board Of Directors
12/13/2005
-
Gilead Sciences (Foster City, CA) Release: Data Show Efficacy Of Standard Dosing Regimen Of AmBisome(R) Is Similar To High Loading Dose For Patients With Invasive Fungal Infections
12/12/2005
-
Gilead Sciences (Foster City, CA) Launches An Educational Website On Advances In Combination Therapy For HIV
12/7/2005
-
Gilead Sciences (Foster City, CA) To Present At The NASDAQ 16th Investor Program
12/5/2005
-
4AZA Bioscience NV Announced Research Collaboration With Gilead Sciences (Foster City, CA)
11/30/2005
-
Gilead Sciences (Foster City, CA) To Present At The Lazard Capital Markets Life Sciences Conference
11/29/2005
-
Nothing Like A Room Full Of Brainiacs To Make A Columnist Feel Small
11/21/2005
-
Gilead Sciences (GILD) Says Truvada Better Than Combivir For HIV
11/18/2005
-
Roche Pays Gilead Sciences (GILD) $62.5M, Royalties To End Tamiflu Dispute
11/16/2005
-
Global Epidemic
11/3/2005
-
The Day In Review: Positive Coley IPO Not Enough For Biotech
8/10/2005
-
The Day In Review: Biotech Makes Gain Before Amgen Earnings
7/19/2005
-
The Day In Review: Small Loss For Biotech
4/27/2005
-
The Day In Review: Biotech Manages To Contain Its Loss
4/20/2005
-
FHI Cancels Nigerian Arm Of Clinical Trial Testing Tenofovir For HIV Prevention
3/17/2005